WNT2 activation through proximal germline deletion predisposes to small intestinal neuroendocrine tumors and intestinal adenocarcinomas

Abstract
Many hereditary cancer syndromes are associated with an increased risk of small and large intestinal adenocarcinomas. However, conditions bearing a high risk to both adenocarcinomas and neuroendocrine tumors are yet to be described. We studied a family with 16 individuals in four generations affected by a wide spectrum of intestinal tumors, including hyperplastic polyps, adenomas, small intestinal neuroendocrine tumors, and colorectal and small intestinal adenocarcinomas. To assess the genetic susceptibility and understand the novel phenotype we utilized multiple molecular methods, including whole genome sequencing, RNA sequencing, single cell sequencing, RNA in situ hybridization, and organoid culture. We detected a heterozygous deletion at the cystic fibrosis locus (7q31.2) perfectly segregating with the intestinal tumor predisposition in the family. The deletion removes a topologically associating domain (TAD) border between CFTR and WNT2, aberrantly activating WNT2 in the intestinal epithelium. These consequences suggest that the deletion predisposes to small intestinal neuroendocrine tumors and small and large intestinal adenocarcinomas, and reveals the broad tumorigenic effects of aberrant WNT activation in the human intestine.
Language
English
Published in
Human Molecular Genetics
Citation
  • Aavikko, M., Kaasinen, E., Andersson, N., Pentinmikko, N., Sulo, P., Donner, I., Pihlajamaa, P., Kuosmanen, A., Bramante, S., Katainen, R., Sipilä, L. J., Martin, S., Arola, J., Carpén, O., Heiskanen, I., Mecklin, J.-P., Taipale, J., Ristimäki, A., Lehti, K., . . . Aaltonen, L. A. (2021). WNT2 activation through proximal germline deletion predisposes to small intestinal neuroendocrine tumors and intestinal adenocarcinomas. Human Molecular Genetics, 30(24), 2429-2440. https://doi.org/10.1093/hmg/ddab206
License
CC BY 4.0Open Access
Additional information about funding
This work was supported by grants from the Academy of Finland's Center of Excellence Program 2012–2017 (#250345) and 2018–2025 (#31204), the Finnish Cancer Society, the Sigrid Juselius Foundation, the Jane and Aatos Erkko Foundation. The following foundations are acknowledged for personal grants: the Helsinki University Hospital Research Grants, Finska Läkaresällskapet, the Biomedicum Helsinki Foundation, the Finnish Cancer Society, the Ida Montini Foundation, the Maud Kuistila Memorial Foundation, the Orion-Farmos Research Foundation, and the Paulo Foundation.
Copyright© 2021 the Authors

Share